Oslo, Norway ,6 October 2021 -Targovax ASA (OSE: TRVX), a clinical stage immuno -oncology company developing immune activators to target hard-to-treat solid tumors, today announces that two abstracts has been accepted for poster presentation at theSociety for Immunotherapy of Cancer (SITC) Annual Meeting. The abstracts will be released on the SITC website 9 November14:00 CEST (www.sitcancer.org/2021/home). The posters are scheduled for presentation during the SITC congress12-14 November 2021 . Poster A randomised open-label phase I/II study adding ONCOS-102 to title: pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma - 24-month survival data E-poster 462 number: Lead DrLuis Paz-Ares , Medical Oncology, Hospital Universitario 12 author: Octubre,Madrid, Spain *** Poster Consistent pattern of immune activation induced by oncolytic title: adenovirus ONCOS-102 across diverse types of solid tumors E-poster 368 number: LeadLukasz Kuryk , PhD, Director Clinical Science,Targovax author: *** About SITCThe Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy. As the largest conference solely focused on cancer immunotherapy, the Annual Meeting & Pre-Conference Programs provides international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients. For further information, please contact:Oystein Soug , CEO Phone: +47 906 56 525 Email: oystein.soug@targovax.comRenate Birkeli , Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media enquires:Andreas Tinglum - Corporate Communications (Norway ) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no AboutTargovax Activating the patient's immune system to fight cancerTargovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors.Targovax aims to unlock greater clinical benefits in cancer patients by deploying its multifunctional platforms to target key immune regulators and oncogenic drivers.Targovax's focus is to "activate the patient's immune system to fight cancer", thus extending and transforming the lives of cancer patients.Targovax's pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The company's product candidates are designed to harness the patient's own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.Targovax's lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both in monotherapy and in multiple combinations, the next development steps for ONCOS-102 will be to further improve responses in melanoma patients resistant to or poorly responsive to current standard of care.
Click here for more information
© Oslo Bors ASA, source